Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma-glutamylcysteine synthetase (GCL), also known as glutamate–cysteine ligase, is a crucial enzyme in the biosynthesis of glutathione. It catalyzes the first and rate-limiting step in glutathione production by facilitating the ATP-dependent condensation of cysteine and glutamate to form gamma-glutamylcysteine (γ-GC). GCL activity dictates cellular levels of GSH, essential for maintaining redox homeostasis and protecting cells from oxidative stress. Altered expression or function can impact chemoresistance in cancer cells. It is a heterodimer composed of a heavy catalytic subunit and a light regulatory subunit.
Inhibition of gamma-glutamylcysteine synthetase leading to decreased glutathione synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-glutamylcysteine Synthetase.